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Abstract: The in vitro resistance of selected red/orange complex periodontal pathogens to tinidazole
was compared with four other antibiotics. Subgingival biofilm samples from 88 adults with
severe periodontitis were anaerobically incubated on enriched Brucella blood agar with and
without supplementation with tinidazole (16 mg/L), metronidazole (16 mg/L), amoxicillin (8 mg/L),
doxycycline (4 mg/L), or clindamycin (4 mg/L). Growth of Porphyromonas gingivalis, Tannerella forsythia,
Prevotella intermedia/nigrescens, Parvimonas micra, Fusobacterium nucleatum, Streptococcus constellatus, or
Campylobacter rectus on antibiotic-supplemented plates indicated their in vitro antibiotic resistance.
Tinidazole inhibited all test species, except P. intermedia/nigrescens, P. micra, and S. constellatus
in 3.8%, 10.2%, and 88.9% of species-positive patients, respectively. Significantly fewer patients
yielded tinidazole-resistant test species, and had significantly lower subgingival proportions of
tinidazole-resistant organisms, than patients with amoxicillin, doxycycline, or clindamycin-resistant
species, but not those with metronidazole-resistant strains. Joint in vitro species resistance to tinidazole
and amoxicillin, or metronidazole and amoxicillin, was rare. Tinidazole performed in vitro similar
to metronidazole, and markedly better than amoxicillin, doxycycline, or clindamycin, against fresh
clinical isolates of red/orange complex periodontal pathogens. As a result of its similar antimicrobial
spectrum, and more convenient once-a-day oral dosing, tinidazole should be considered in place of
metronidazole for systemic periodontitis drug therapy.
Keywords: anti-infective agents; periodontitis; drug resistance; in vitro; periodontal pocket;
tinidazole; metronidazole; doxycycline; amoxicillin; clindamycin
1. Introduction
Human periodontitis is a destructive form of periodontal disease that is triggered by pathogenic
bacterial biofilms, possibly in synergy with certain lytic herpesviruses [1], and mediated by dysregulated
host hyper-inflammatory responses, causing progressive connective tissue attachment loss and
alveolar bone resorption around teeth, ultimately leading to their loss from the oral cavity [2].
Among the approximately 700 known microbial species and uncultivated phylotypes that inhabit
the human oral cavity, only a subset is associated with a pathogenic subgingival microbial dysbiosis
in periodontitis-affected patients [3]. Socransky et al. [4], using DNA hybridization data, identified
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several clusters of bacteria as significantly related to various periodontal clinical conditions, with
species belonging to the red and orange complex clusters most strongly associated with severe
forms of periodontitis. The same red/orange complex species were also identified as part of the core
subgingival microbiome of severe human periodontitis lesions in more recent studies using next
generation gene sequencing [5,6]. Importantly, all red complex (Porphyromonas gingivalis, Tannerella
forsythia, and Treponema denticola), and most orange complex species (including Prevotella intermedia,
Prevotella nigrescens, Parvimonas micra, and Fusobacterium nucleatum group species, but not Streptococcus
constellatus or Campylobacter rectus), are obligate anaerobic microorganisms, indicative of a strong
association that exists between specific anaerobic bacteria and severe periodontitis [7].
Related to this, oral administration of metronidazole, which is highly active against anaerobic
bacteria, is beneficial in enhancing therapeutic outcomes in severe periodontitis patients beyond that
attained by conventional mechanically-based forms of periodontal therapy alone [8–13], due in large
part to a significantly greater suppression of subgingival red/orange complex species achieved with
systemic metronidazole therapy [14–17].
However, patient compliance with taking systemic metronidazole, which is most often prescribed
to be taken orally three times per day for 7–14 days [18–20], is critical to the drug’s potential value
in periodontal therapy. In a clinical trial, only 56% of the study patients were considered adequately
compliant with taking systemic metronidazole tablets at the prescribed frequency of three times per
day as an adjunct to conventional periodontal root debridement therapy, with compliant patients
experiencing significantly better periodontal treatment outcomes that were more than double in
magnitude as found in less compliant patients [21].
Tinidazole, a second-generation 2-methyl-5-nitroimidazole class antibiotic structurally similar to
metronidazole, which exerts marked bactericidal activity against anaerobic bacteria and protozoa [22],
may help overcome these patient compliance problems, and serve as a potential alternative to
metronidazole and other antibiotics in combatting periodontal infections. Tinidazole possesses
pharmacokinetic properties which enables once-a-day oral systemic drug dosing [23], a medication
frequency associated with markedly better patient consumption compliance [24]. However, tinidazole,
which was first clinically employed in 1969 for Trichomonas vaginalis infections [25], and approved for
use in the United States by the Food and Drug Administration in 2004 [26], has to date received relatively
little research attention for its potential administration in human periodontal disease therapy [27].
Systemic tinidazole has shown efficacy in treatment of pericoronitis lesions and acute periodontal
abscesses [28], was reported to provide a subjectively higher effective treatment rate in periodontitis
patients than systemic metronidazole (73.1% versus 43.5%) [29], and in smoking periodontitis patients,
induced significantly more favorable changes in probing depth, clinical periodontal attachment level,
and gingival inflammation than conventional periodontal root scaling alone [30]. Only limited data are
presently available on the antimicrobial effects of tinidazole on various putative human periodontal
bacterial pathogens [31,32], particularly in comparison to other potential systemic periodontal antibiotic
drug choices [18–20].
To further advance consideration of tinidazole in periodontal disease management, this study
determined and compared the prevalence and levels of in vitro resistance among fresh clinical isolates
of selected red/orange complex bacterial species from severe periodontitis patients to tinidazole and
four other antibiotics often systemically employed in human periodontal disease therapy.
2. Materials and Methods
2.1. Microbial Specimens
Subgingival plaque biofilm specimens were used from 88 systemically healthy, non-smoking adults
(34 male, 54 female; mean age = 57.2 ± 13.3 (standard deviation, SD) years; age range = 35–83 years
old) with severe periodontitis from whom subgingival samples were consecutively submitted by
USA private practicing periodontists for microbiological analysis and antibiotic resistance testing to
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metronidazole, amoxicillin, doxycycline, and clindamycin at the Oral Microbiology Testing Service
(OMTS) Laboratory at Temple University School of Dentistry, Philadelphia, PA, USA, which is licensed
for high complexity bacteriological analysis by the Pennsylvania Department of Health. Samples
from patients identified with aggressive periodontitis or antibiotic use 6 months before sampling were
excluded. The subgingival specimens, which are normally discarded by the OMTS Laboratory after
completion of requested microbiological testing, were additionally used in this study for tinidazole
in vitro resistance testing after removal of all unique patient identifiers.
2.2. Microbial Sampling and Transport
The subgingival specimens were obtained with sterile paper points by the treating periodontists
from 3–5 periodontal sites exhibiting deep periodontal probing depths (≥7 mm) and bleeding on
probing, following standardized sampling procedures previously described [33]. All paper points per
patient were pooled into a single glass vial containing pre-reduced, anaerobically sterilized and stored
Möller’s VMGA III transport medium [34], and delivered within 24 hours to the OMTS Laboratory.
2.3. Microbial Culture
The microbial specimens were processed as previously described [33], with aliquots of serial
10-fold dilutions inoculated onto enriched Brucella blood agar (EBBA) plates with either no antibiotics
added, or supplemented with non-susceptible breakpoint concentrations of either tinidazole (16 mg/L),
metronidazole (16 mg/L), amoxicillin (8 mg/L), doxycycline (4 mg/L), or clindamycin (4 mg/L) (all
antibiotics obtained as pure powder from Sigma-Aldrich, St. Louis, MO, USA). The breakpoint
concentration values for metronidazole, amoxicillin, doxycycline, and clindamycin were employed in
previous periodontal and dental implant microbiology studies [33,35], and represent drug levels
at or above minimal inhibitory concentrations associated with the “susceptible” interpretative
category for anaerobic bacteria as recognized by the Clinical and Laboratory Standards Institute
(CLSI) [36], or the French Society for Microbiology (for doxycycline) [37]. The 16 mg/L non-susceptible
breakpoint concentration for metronidazole was also used for tinidazole in this study, since breakpoint
concentrations for tinidazole are not established, but are considered to be equivalent to those for
metronidazole [32]. All inoculated EBBA plates were incubated at 37 ◦C for 7 days in a upright
heated incubator (Caron, Marietta, OH, USA) in jars containing an 85% N2-10% H2-5% CO2 anaerobic
atmosphere introduced by an automatic jar evacuation-replacement system (Anoxomat Mark II,
Advanced Instruments, Inc., Norwood, MA, USA).
2.4. Microbial Identification
After incubation, established phenotypic criteria [33] were used to quantitate total anaerobic
viable counts, and determine the presence and proportional recovery of selected red/orange complex
species, including P. gingivalis, T. forsythia, P. intermedia/nigrescens, P. micra, F. nucleatum group species,
S. constellatus, and C. rectus.
In brief, P. gingivalis was identified as circular, dome-shaped, dark-pigmented (brown to
tan), raised surfaces colonies that lacked brick-red autofluorescence under long-wave ultraviolet
light, but exhibited trypsin-like enzyme activity. T. forsythia was identified as Gram-negative,
non-motile, anaerobic rods exhibiting gray-pink speckled, convex, pinpoint colonies seen with a
stereomicroscope, lack of long-wave ultraviolet light autofluorescence, and positive for trypsin-like
enzyme activity. P. intermedia/nigrescens identification was based on their appearance as circular,
dome-shaped, dark-pigmented (black to brown), raised surface colonies displaying an autofluorescent
brick-red color under long-wave ultraviolet light exposure, and testing negative for lactose fermentation
activity. P. micra presented as Gram-positive, non-motile, anaerobic cocci exhibiting small (minute to
1.0 mm in diameter), shiny, non-hemolytic, catalase-negative, opaque white, circular, convex surface
colonies. F. nucleatum group species were identified as long-wave ultraviolet light autofluorescent
charteuse-positive, gray, iridescent colonies of Gram-negative, filamentous, spindle-shaped, non-motile
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rods. S. constellatus was defined as Gram-positive, lactose-negative, non-motile, facultative cocci
demonstrating small white, opaque, circular, β-hemolytic, surface colonies with irregular edges, and
positive for α-D-glucosidase enzyme activity. C. rectus was identified on the basis of mobility, cellular
morphology, and the formation of small (1–3 mm), catalase and oxidase-negative, pale-translucent
colonies appearing as either corroding, spreading, or convex variants.
P. intermedia was not differentiated from P. nigrescens, but a subset of isolates phenotypically
identified as P. intermedia/nigrescens were confirmed to be either P. intermedia or P. nigrescens with
matrix-assisted laser desorption-ionization time-of-flight (MALDI-TOF) mass spectrometry and Bruker
MALDI Biotyper analytic software (Bruker Daltonics, Billerica, MA, USA), following procedures
previously described [38,39]. This method was also used to confirm species identification of other
selected clinical isolates of test species. Proportional patient recovery of test species per subgingival
specimen was calculated as the percent recovery of colony forming units (CFU) of the species among
total cultivable anaerobic viable counts as determined on non-antibiotic supplemented EBBA plates.
2.5. In Vitro Antibiotic Resistance Testing
Growth of test species on antibiotic-supplemented EEBA plates indicated their in vitro resistance
to the evaluated antibiotic breakpoint concentration [33,35]. This direct plating method, with
non-susceptible antibiotic breakpoint concentrations incorporated into primary isolation plates, has
shown excellent correlation (r2 = 0.99) with the CLSI-approved agar dilution susceptibility assay for
identification of antibiotic-resistant periodontal microorganisms [40]. Bacteroides thetaiotaomicron ATCC
29741, Clostridium perfringens ATCC 13124, and a multi-antibiotic-resistant clinical periodontal isolate
of F. nucleatum were used as positive and negative quality controls for all antibiotic resistance testing
on antibiotic-supplemented EBBA plates.
2.6. Laboratory Protocol and Study Approval
All laboratory procedures were performed following a standardized protocol by same laboratory
personnel, who were masked to the clinical status and diagnosis of the sampled patients, and their
inclusion into the present study. Approval for the study was provided by the Temple University Human
Subjects Institutional Review Board, which determined that secondary use of normally discarded
subgingival specimens not linked to the identification of any person(s) did not qualify as human
subjects research requiring written patient consent since patient identities and contact information
were not known, and no investigator-study patient contact, interaction, or intervention was carried out.
2.7. Data Analysis
For each of the evaluated red/orange complex species, the number and proportion of
species-positive patients from non-antibiotic containing EBBA plates was determined, along with its
mean cultivable subgingival proportional recovery and SD, as well as the number and proportion of
patients positive for antibiotic-resistant strains of the species, and proportional recovery of drug-resistant
strains on various antibiotic-supplemented EBBA plates. Fisher’s exact test compared among patients
the presence one or more tinidazole-resistant red/orange species, as compared to the presence in patients
of metronidazole, amoxicillin, doxycycline, or clindamycin-resistant test species. Total cultivable
subgingival proportions of red/orange complex species per patient were determined by summing
together individual species data for each patient, and then calculating total mean values across all
patients, as previously described [41]. A paired t-test compared mean total cultivable subgingival
proportions of red/orange complex species per patient resistant in vitro to tinidazole, as compared to
mean proportions per patient resistant to either metronidazole, amoxicillin, doxycycline, or clindamycin.
In vitro antibiotic-resistance data for tinidazole and metronidazole were each combined post hoc with
those for amoxicillin, and compared per study patient, as previously described [33,35], to determine
the number and proportion of patients with test species exhibiting joint in vitro resistance to both
antibiotics at the employed breakpoint concentrations, since the combination of metronidazole plus
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amoxicillin is frequently employed in the treatment of human periodontitis [19]. A p-value of ≤0.05 was
required for all tests of statistical significance. The PC-based STATA/SE 16.0 for Windows (StataCorp
PL, College Station, TX, USA) 64-bit statistical software package was used in the data analysis.
3. Results
3.1. Total Cultivable Counts
Total cultivable subgingival anaerobic viable counts on EBBA plates without any added antibiotics
averaged 1.7× 108 ± 1.3× 108 (SD) organisms/mL of sample (range = 2.0× 107 to 5.0× 108 organisms/mL).
3.2. Red/Orange Complex Species Recovery
Table 1 lists the presence and subgingival proportional recovery of evaluated red/orange complex
species in subgingival biofilm specimens from 88 adults with severe periodontitis.
Table 1. Red/orange complex species recovered from study patients.
Test Species No. (%) of PositivePatients





P. gingivalis 9 (10.2) 10.1 (6.6) 1.0–21.0
T. forsythia 47 (53.4) 2.3 (1.9) 0.2–10.5
Orange Complex Species:
P. intermedia/nigrescens 80 (90.9) 7.1 (9.9) 0.1–46.7
P. micra 88 (100) 7.9 (6.3) 0.2–40.0
F. nucleatum 73 (83.0) 8.5 (6.4) 0.7–32.6
S. constellatus 9 (10.2) 7.4 (4.5) 2.4–13.3
C. rectus 13 (40.9) 0.2 (0.2) 0.1–1.0
* calculated as the average percent CFU recovery of the species among total cultivable anaerobic viable counts as
determined on non-antibiotic supplemented EBBA plates among patients culture-positive for the test species.
P. micra was isolated from all of the study patients, and P. intermedia/nigrescens and F. nucleatum
from 90.9% and 83.0% patients, respectively, with mean subgingival proportions of these species in
culture-positive patients ranging from 7.1% to 8.5%. T. forsythia was recovered from 53.4% of the
patients, and P. gingivalis from 10.2% patients. Total cultivable subgingival proportions of evaluated
red/orange complex species per patient averaged 24.5 ± 17.3 (SD) % on non-antibiotic containing
EBBA plates.
3.3. In Vitro Antibiotic Resistance Testing
Table 2 lists the number and percentage of patients with red/orange complex species exhibiting
in vitro resistance to the evaluated antibiotic breakpoint concentrations.
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Table 2. Patients with antibiotic-resistant red/orange complex species (antibiotic concentration).










P. gingivalis N * 0 0 1 (11.1) 0 2 (22.2)
% † 0 0 7.6 0 5.5 ± 6.4
T. forsythia N 0 0 14 (29.8) 5 (10.6) 25 (53.2)
% 0 0 2.7 ± 1.4 3.2 ± 1.7 2.4 ± 1.6
Orange Complex Species:
P. intermedia/nigrescens N 3 (3.8) 1 (1.3) 40 (50.0) 38 (47.5) 47 (58.8)
% 14.7 ± 14.6 2.8 9.1 ± 10.4 8.2 ± 11.5 7.3 ± 9.7
P. micra
N 9 (10.2) 2 (2.3) 2 (2.3) 34 (38.6) 48 (54.6)
% 10.1 ± 5.8 9.3 ± 9.5 4.2 ± 1.3 8.4 ± 5.8 8.2 ± 6.7
F. nucleatum
N 0 0 2 (2.7) 3 (4.1) 0
% 0 0 7.9 ± 2.9 6.5 ± 3.1 0
S. constellatus
N 8 (88.9) 9 (100) 0 2 (22.2) 0
% 7.4 ± 4.5 7.4 ± 4.5 0 11.3 ± 2.9 0
C. rectus
N 0 0 0 0 0
% 0 0 0 0 0
TIN = tinidazole. MET = metronidazole. AMOX = amoxicillin. DOXY = doxycycline. CLIN = clindamycin. *
Number (%) of patients with antibiotic-resistant strains of species among total species-positive patients. †Mean ±
SD percentage cultivable recovery of antibiotic-resistant strains of species in positive patients.
Tinidazole inhibited in vitro growth of all P. gingivalis isolates from 9 patients, T. forsythia from
47 patients, F. nucleatum from 73 patients, and C. rectus from 13 patients (Table 2). However, tinidazole
failed to inhibit in vitro growth of P. intermedia/nigrescens from 3 (3.8%) of 80 species-positive patients,
P. micra from 9 (10.2%) of 88 patients, and S. constellatus from 8 (88.9%) of 9 patients (Table 2).
Metronidazole exhibited similar in vitro drug resistance patterns as tinidazole (Table 2), except for
significantly less in in vitro resistance by P. micra clinical isolates to metronidazole as compared to
tinidazole (p < 0.05, Fisher’s exact test). In vitro resistance to amoxicillin, doxycycline, and clindamycin
by the evaluated red/orange complex species was significantly greater than was found to tinidazole
or metronidazole (all p-values < 0.05, Fisher’s exact test). This increased resistance of red/orange
complex species was particularly pronounced to clindamycin, where subgingival isolates of T. forsythia,
P. micra, and P. intermedia/nigrescens were resistant in vitro to clindamycin among more than 50% of
species-positive patients (Table 2).
Table 3 presents the prevalence among patients, and mean total cultivable subgingival proportions
of red/orange complex species per patient resistant to the test antibiotics, including post-hoc combination
of data for tinidazole plus amoxicillin, and metronidazole plus amoxicillin.
Table 3. Presence and levels of antibiotic-resistant red/orange complex species per patient.
Antibiotic (Breakpoint
Concentration)
No. (%) Patients Positive
with Drug-Resistant
Red/Orange Complex Species
Mean (SD) Total Cultivable Subgingival
Proportions of Drug-Resistant Red/Orange
Complex Species Per Patient
clindamycin (4 mg/L) 68 (77.3) 9.9 (12.2)
doxycycline (4 mg/L) 54 (61.4) 7.2 (10.7)
amoxicillin (8 mg/L) 47 (53.4) 4.7 (8.7)
tinidazole (16 mg/L) 21 (23.9) 2.5 (5.6)
metronidazole (16 mg/L) 12 (13.6) 1.0 (3.1)
tinidazole (16 mg/L) plus
amoxicillin (8 mg/L) * 3 (3.8) 0.5 (3.5)
metronidazole (16 mg/L)
plus amoxicillin (8 mg/L) * 1 (1.3) 0.03 (0.3)
* Post-hoc combination of in vitro resistance data for both antibiotics.
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Patients positive with tinidazole-resistant red/orange complex species (23.9%) were significantly
less prevalent than patients positive with amoxicillin (53.4%), doxycycline (61.4%), or clindamycin-
resistant (77.3%) test species (all p values < 0.001, Fisher’s exact test), but not those with
metronidazole-resistant strains (13.6%) (p = 0.08, Fisher’s exact test). Post-hoc combination of
in vitro resistance data for tinidazole plus amoxicillin, and for metronidazole plus amoxicillin, revealed
both of these antibiotic combinations able to inhibit all red/orange complex species among the study
patients, except for a subset of P. intermedia/nigrescens clinical isolates resistant to both tinidazole and
amoxicillin for 3 patients, and resistant to both metronidazole and amoxicillin for one patient.
Mean total cultivable subgingival proportional levels of tinidazole-resistant red/orange complex
species per patient (2.5%) were significantly less than cultivable proportions per patient found with
amoxicillin (4.7%), doxycycline (7.2%), and clindamycin (9.9%) (all p-values < 0.05, paired t-test), but not
with metronidazole (1.0%), which were significantly lower than with tinidazole (p < 0.01, paired t-test)
(Table 3). No significant differences were found between data combined post-hoc for tinidazole plus
amoxicillin, as compared to metronidazole plus amoxicillin, relative to mean cultivable subgingival
proportional levels of jointly-resistant red/orange complex species per patient (0.5 ± 3.5 (SD) % versus
0.02 ± 0.14 (SD) %, respectively; p = 0.195, paired t-test).
4. Discussion
The major finding from this study is that tinidazole performed similar to metronidazole, and
markedly better than amoxicillin, doxycycline, and clindamycin, with regard to in vitro inhibition of
fresh clinical isolates of red/orange complex periodontal pathogens recovered from adults with severe
periodontitis. Significantly fewer patients yielded tinidazole-resistant test species, and had significantly
lower cultivable subgingival proportional levels of tinidazole-resistant organisms per patient, than
patients with amoxicillin, doxycycline, or clindamycin-resistant species. The prevalence of patients
with one or more tinidazole-resistant red/orange complex species was not significantly different from
those with metronidazole-resistant isolates, but cultivable subgingival levels of test species per patient
resistant to tinidazole were significantly higher than those resistant to metronidazole. Only P. micra,
among the evaluated red/orange complex species, exhibited significantly more in vitro resistance to
tinidazole than metronidazole, even though 89.8% of P. micra-positive patients had all clinical isolates
of the organism susceptible to 16 mg/L of tinidazole. These in vitro antibiotic resistance findings are
clinically relevant to the selection of systemic antibiotics to be potentially employed in periodontitis
therapy since antibiotics ineffective in vitro against major periodontal pathogens under ideal laboratory
test conditions with planktonic microbial cells are unlikely to be of much therapeutic benefit against
periodontal pocket microbial biofilms during in vivo administration [7].
This study also provides the first published data on in vitro susceptibility to tinidazole among
subgingival P. gingivalis, T. forsythia, P. micra and C. rectus from severe periodontitis patients, and
all clinical isolates of these species were found to be susceptible to clinically-attainable therapeutic
concentrations of tinidazole as well as metronidazole. The low frequency of tinidazole resistance
by P. intermedia/nigrescens from 80 patients (3.8%), and none by F. nucleatum from 73 patients, in the
present study are in agreement with a previous report where only one of 10 periodontal P. intermedia
isolates, and none of 10 periodontal F. nucleatum strains, exhibited in vitro resistance to 16 mg/L of
tinidazole [31].
Neither tinidazole nor metronidazole were found to be effective in vitro against S. constellatus,
a Gram-positive facultative cocci implicated in progressive periodontitis, and poorly susceptible to
imidazole class antibiotics [33,42], including tinidazole [43]. This was expected since tinidazole has only
limited antimicrobial activity against non-anaerobic bacteria [44–46], which do not possess ferredoxin
or flavodoxin-like metabolic pathways needed for intracellular tinidazole drug reduction and formation
of redox intermediate metabolites that interfere with microbial nucleic acid synthesis [27,44,47]. Thus,
for severe periodontitis patients jointly colonized by high subgingival levels of both anaerobic and
facultative periodontal pathogens (such as anaerobic red/orange complex species and facultative
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S. constellatus and/or Aggregatibacter actinomycetemcomitans), combined use of tinidazole with another
antibiotic having a complementary but different range of antimicrobial activity may be indicated to
broaden the antimicrobial spectrum of drug chemotherapy [7,18,33]. This was done in a clinical study of
diabetes-associated periodontitis patients, where a systemic combination of tinidazole plus ampicillin
was prescribed as an adjunct to conventional mechanical-surgical periodontal therapy [48]. The present
in vitro study findings show that tinidazole plus amoxicillin would provide similar broad-spectrum
antimicrobial activity as metronidazole plus amoxicillin, a drug combination frequently employed
in human periodontal disease treatment [19]. Tinidazole additionally has been shown to exhibit
antimicrobial synergism in vitro in combination with either amoxicillin/clavulanic acid, levofloxacin, or
clindamycin against a mixed bacterial inoculum of periodontal origin [32]. Pharmacokinetic studies are
needed to determine the best dosing schedules for such possible combined antibiotic regimens in light
of differing half-life values for tinidazole and other non-imidazole antibiotics, such as amoxicillin [27].
Since tinidazole has a 12–14 hour serum half-life, which is approximately double that found
with metronidazole [49], providing mean gingival crevicular fluid concentrations of 13 mg/L of
tinidazole at 24 hours after a single 2-gram oral dose [23], tinidazole requires less frequent daily
patient dosing than metronidazole, and thereby offers an advantage over metronidazole relative to
attaining patient compliance with prescribed drug consumption frequency. As a result of these more
favorable pharmacokinetic properties permitting a more convenient once-a-day oral dose schedule for
tinidazole, its similar array of potential side effects and drug interactions as metronidazole [26], and its
similar antimicrobial activity against red/orange complex periodontal pathogens as metronidazole,
as documented in the present study, tinidazole should be considered in place of metronidazole for
systemic periodontitis drug therapy, particularly when patient compliance with a multiple dose
per day drug regimen is anticipated to be poor or difficult to attain. This would be in accord
with findings that patient compliance with drug dosing improves as the prescribed dose frequency
decreases [24], and recommendations that medications be favored that have the lowest daily prescribed
dose frequency [24]. However, systemic use of tinidazole, as well as with all other antibiotics in
periodontal therapy, should be selective in nature and reserved mostly for periodontitis patients having
a poor clinical outcome, and/or elevated persistence of key periodontal pathogens, after completion of
conventional mechanical periodontal treatment [18,50]. Periodontal microbiology laboratory analysis
may assist dental professionals in reducing the risk of therapeutic failure inherent with empirically
prescribed systemic periodontal antibiotic therapy [51] by identifying periodontal pathogens with
either predictable antibiotic susceptibility patterns or which display in vitro resistance to antibiotics
under consideration for in vivo use [7]. This approach will help limit overall patient exposure to
antibiotics, reduce development of adversely altered microbial populations at non-oral body sites, and
lower the risk of increased antibiotic resistance in the human microbiome. Additional in vitro and
clinical research is needed to further evaluate the potential use and efficacy of tinidazole in treatment
of human periodontal disease.
5. Conclusions
In vitro resistance to tinidazole was similar to metronidazole among fresh clinical isolates of
red/orange complex periodontal pathogens from severe periodontitis patients, and markedly less
than to amoxicillin, doxycycline, or clindamycin. As a result of its similar antimicrobial spectrum
against red/orange complex periodontal pathogens, and more convenient once-a-day oral drug dosing,
tinidazole should be considered in place of metronidazole for systemic periodontitis drug therapy
when it is clinically and/or microbiologically indicated, particularly when patient compliance with a
multiple dose per day drug regimen is anticipated to be poor or difficult to attain.
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